《大行報告》匯豐研究上調國藥(01099.HK)目標價至25元 升上海醫藥(02607.HK)目標價至19.9元
匯豐研究發表研報指,今年內地藥房股股價表現較差,過去六個月內回落幅度達20%,對比同期滬深300指數下跌約9%,主要反映出去年第四季至今年首季藥房股仍然受到疫情影響,導致增長放緩。
該行認為,行業整合及政策主導處方藥數量增加的趨勢,將推動藥房股龍頭企業今年盈利平均增長約23%。但考慮到下半年經濟放緩、盈利基礎較高以及政策改革步伐與影響存在不確定性,該行認為行業目前的估值處於合理水平。
匯豐研究對內地藥房股2023至2024年每股盈測作調整,由下調4%至上調11%不等,目標價調整幅度則介乎下調43%至上調13%。現時匯豐研究首選為大參林(603233.SH)及上海醫藥(02607.HK)(601607.SH),均予「買入」評級,其中上藥H股目標價由17.3元升至19.9元。
另外,該行亦將國藥(01099.HK)H股目標價從22.5元升至25元,維持「持有」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.